Article in Proceedings of SPIE--the International Society for Optical Engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Chongyu QuVanderbilt University, Nashville TN 37235, USA.
Allen J LunaVanderbilt University Medical Center, Nashville TN 37232, USA.
Thomas Z LiVanderbilt University, Nashville TN 37235, USA.
Junchao ZhuVanderbilt University, Nashville TN 37235, USA.
Junlin GuoVanderbilt University, Nashville TN 37235, USA.
Juming XiongVanderbilt University, Nashville TN 37235, USA.
Kim L SandlerVanderbilt University Medical Center, Nashville TN 37232, USA.
Bennett A LandmanVanderbilt University, Nashville TN 37235, USA.
Yuankai HuoVanderbilt University, Nashville TN 37235, USA.
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
Validation of Biomarkers of Risk for the Early Detection of Lung CancerU01CA152662 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DEPPEN, STEPHEN, GROGAN, ERIC L · 2010 to 2025
$12.8M
Cellular, molecular and quantitative imaging analysis of screening-detected lung adenocarcinomaU01CA196405 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MALDONADO, FABIEN · 2015 to 2020
$5.4M
Novel Integrative Approach for the Early Detection of Lung Cancer using Repeated MeasuresR01CA253923 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LANDMAN, BENNETT A., MALDONADO, FABIEN · 2021 to 2025
$3.4M
Integrating imaging and biopsy-derived molecular markers for the pre-surgical detection of indolent and aggressive early stage lung adenocarcinomaR01CA275015 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Marc Elliott Lenburg, Fabien Maldonado · 2023 to 2026
$2.6M
Training Program for Innovative Engineering Research in Surgery and InterventionT32EB021937 · NIBIB · VANDERBILT UNIVERSITY · PI Dario J Englot, Michael Ian Miga · 2016 to 2026
$2.3M
Risk stratifying indeterminate pulmonary nodules with jointly learned features from longitudinal radiologic and clinical big dataF30CA275020 · NCI · VANDERBILT UNIVERSITY · PI LI, THOMAS ZHIHE · 2023 to 2025
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Cohort-Aware Agents for Individualized Lung Cancer Risk Prediction Using a Retrieval-Augmented Model Selection Framework. · full record | OpenQuestion